{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:17:49Z","timestamp":1761715069429,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pcd.2017.02.004","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T23:17:20Z","timestamp":1489533440000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study"],"prefix":"10.1016","volume":"11","author":[{"given":"Maja","family":"Cigrovski Berkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davorka","family":"Herman Mahe\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Gradi\u0161er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Bili\u0107-\u0106ur\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)","author":"National Collaborating Centre for Chronic Conditions","key":"10.1016\/j.pcd.2017.02.004_bib0005"},{"key":"10.1016\/j.pcd.2017.02.004_bib0010","first-page":"S1","article-title":"Standards of medical care in diabetes-2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pcd.2017.02.004_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-5491.2006.01918.x","article-title":"Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care","volume":"23","author":"IDF Clinical Guidelines Task Force","year":"2006","journal-title":"Diabet. Med."},{"issue":"6","key":"10.1016\/j.pcd.2017.02.004_bib0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.pcd.2017.02.004_bib0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1R444","article-title":"Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors","volume":"47","author":"Boland","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"Suppl. 2","key":"10.1016\/j.pcd.2017.02.004_bib0030","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.2337\/dcS13-2012","article-title":"How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment","volume":"36","author":"Gallwitz","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2017.02.004_bib0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/qjmed\/hcr015","article-title":"Which oral agent to use when metformin is no longer effective","volume":"104","author":"Bannon","year":"2011","journal-title":"Q. J. Med."},{"issue":"4","key":"10.1016\/j.pcd.2017.02.004_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2009.03.003","article-title":"Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin\u2014diabetes control and potential adverse events","volume":"23","author":"Ahr\u00e9n","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.pcd.2017.02.004_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3310\/hta15suppl1-09","article-title":"Liraglutide for the treatment of type 2 diabetes","volume":"15","author":"Shyangdan","year":"2011","journal-title":"Health Technol. Assess."},{"issue":"4","key":"10.1016\/j.pcd.2017.02.004_bib0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1474651410377832","article-title":"SGLT2 inhibitors: glucuretic treatment for type 2 diabetes","volume":"10","author":"Bailey","year":"2010","journal-title":"Br. J. Diabetes Vasc. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.pcd.2017.02.004_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/dmrr.2350","article-title":"Second line therapy: type 2 diabetic subjects failing on metformin GLP-1\/DPP-IV inhibitors versus sulphonylurea\/insulin: for GLP-1\/DPP-IV inhibitors","volume":"28","author":"Kumar","year":"2012","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"2","key":"10.1016\/j.pcd.2017.02.004_bib0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab."},{"issue":"36","key":"10.1016\/j.pcd.2017.02.004_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14360","article-title":"Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation","volume":"14","author":"Waugh","year":"2010","journal-title":"Health Technol. Assess."},{"issue":"Suppl. 17","key":"10.1016\/j.pcd.2017.02.004_bib0070","first-page":"8","article-title":"Hrvatske smjernice za lije\u010denje \u0161e\u0107erne bolesti tipa 2 (Croatian guidelines for treatment of diabetes mellitus type 2)","author":"Koki\u0107","year":"2011","journal-title":"Medix"},{"key":"10.1016\/j.pcd.2017.02.004_bib0075","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2017.02.004_bib0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2007-979906","article-title":"\u201cJ\u201d-index: a new proposition of the assessment of current glucose control in diabetic patients","volume":"27","author":"Wojcicki","year":"1995","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.pcd.2017.02.004_bib0085","first-page":"35","article-title":"Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis","volume":"5","author":"McIntosh","year":"2011","journal-title":"Open Med."},{"issue":"6","key":"10.1016\/j.pcd.2017.02.004_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcjd.2013.04.008","article-title":"Use patterns of antidiabetic regimens by patients with type 2 diabetes","volume":"37","author":"Abdelmoneim","year":"2013","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.pcd.2017.02.004_bib0095","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.pcd.2017.02.004_bib0100","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","article-title":"Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes","volume":"34","author":"Riddle","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pcd.2017.02.004_bib0105","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","volume":"16","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.pcd.2017.02.004_bib0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrendo.2014.170","article-title":"Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications","volume":"10","author":"Frier","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.pcd.2017.02.004_bib0115","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4158\/EP13005.RA","article-title":"Hypoglycemia: minimizing its impact in type 2 diabetes","volume":"19","author":"Moghissi","year":"2013","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.pcd.2017.02.004_bib0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2017.02.004_bib0125","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2017.02.004_bib0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pcd.2017.02.004_bib0135","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.endonu.2013.04.011","article-title":"Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study","volume":"60","author":"Sicras-Mainar","year":"2013","journal-title":"Endocrinol. Nutr."},{"year":"2014","series-title":"Euro Diabetes Index 2014 Report","author":"Garrofe","key":"10.1016\/j.pcd.2017.02.004_bib0140"},{"issue":"8","key":"10.1016\/j.pcd.2017.02.004_bib0145","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175199181730027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175199181730027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:56:05Z","timestamp":1761695765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S175199181730027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S175199181730027X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2017.02.004","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2017.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}